Corvus Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDCorvus Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings contraction of 15% provides fundamental context to the price action. Investors should exercise caution due to high volatility (69% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $12.10 | +19.70% | ABOVE |
| 50 SMA | $13.62 | +6.30% | ABOVE |
| 100 SMA | $14.98 | -3.36% | BELOW |
| 150 SMA | $13.66 | +6.00% | ABOVE |
| 200 SMA | $12.06 | +20.06% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CRVS in an uptrend right now?
CRVS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CRVS overbought or oversold?
CRVS's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is CRVS outperforming the market?
CRVS has a Relative Strength (RS) Rating of 81 out of 99. Yes, CRVS is a market leader, outperforming 81% of all stocks over the past 12 months.
Where is CRVS in its 52-week range?
CRVS is trading at $14.48, which is 54% of its 52-week high ($26.95) and 46% above its 52-week low ($3.71).
How volatile is CRVS?
CRVS has a Beta of 1.77 and 52-week volatility of 69%. It's more volatile than the S&P 500 - expect bigger swings.